Monday, November 16, 2026
Noti Group
Business

Novo Publishes Final Results of Wegovy Trial in Children Aged 6 to Under 12 with Obesity

A late-stage trial investigating Novo's Wegovy injection found that the treatment significantly reduced body mass index (BMI) compared to a placebo at 68 weeks.

Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Source: CNBC

Novo has published the final results of a late-stage trial investigating its popular Wegovy injection in children aged 6 to under 12 with obesity.

The study found that Wegovy significantly reduced body mass index (BMI) compared to a placebo at 68 weeks, demonstrating promising potential for treating childhood obesity. The average reduction in BMI was estimated to be 19.7 percentage points more than the placebo group. This improvement occurred even when patients continued treatment throughout the trial period.

The trial involved all 167 children receiving lifestyle modifications, including a reduced-calorie diet and increased physical activity, alongside Wegovy injections. Among those who stayed on treatment, the average BMI fell by 17.4%, while it rose by 2.2% in the placebo group.

Childhood obesity can have severe long-term health consequences if left untreated, including cardiovascular and metabolic issues. The condition often persists into adulthood, bringing additional complications. Novo's Wegovy trial results offer a potential breakthrough in addressing this chronic disease affecting young children.

The World Obesity Federation estimates that by 2040, nearly a quarter of a billion children and teens worldwide will be affected by obesity. This staggering figure is projected to rise from an estimated 177 million in 2025.

Moderate to severe obesity affects the majority of children participating in Novo's Wegovy trial. A whopping 85% of participants started with BMIs above 35, while nearly a third had BMIs exceeding 40.

The presence of obesity-related complications among young patients is alarming. Nearly half of the children in the trial already suffered from conditions such as high blood pressure, high cholesterol, or sleep apnea.

More than four out of ten children treated with Wegovy no longer met the criteria for obesity after 68 weeks, assuming they remained on treatment. This promising result has significant implications for addressing childhood obesity, a pressing concern globally.

The findings from this trial are particularly significant because it's clear that early intervention can make a substantial difference in preventing the progression of childhood obesity into more severe forms.

Novo reported that Wegovy's safety profile for children was comparable to that observed in adult trials, with no notable concerns related to growth or puberty. The company also noted that patients generally tolerated the treatment well, mirroring the experience of adults who have received the medication.

While this trial provides valuable insights into the potential benefits of early obesity treatment, it's essential to acknowledge that further research is needed to fully understand its long-term implications for children as they transition into adulthood and beyond.

Facts based on reporting originally published by CNBC.

You may republish this story, in full or in part, if you credit Noti Group and link to it (licence CC BY 4.0). Photos are not included.